24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Helsinn
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:05
NextVision hits $5 billion valuation after landing record $77 million drone camera deal
12:29
Navan shares extend decline as losses widen and CFO plans exit
09:55
The calm town at the center of the quantum race
09:24
The OpenAI security breach: The information you share with ChatGPT may leak
More stories
Buzz
Most popular
Daily
Weekly
1
“Younger people are getting cancer more and more. We have to make kinder medicines.”
2
The $2.3 billion mystery arms deal Israel won’t explain
3
Shipping giant MSC submits bid for ZIM, challenging Hapag-Lloyd in takeover race
4
“The acquisition of Armis marks a clear entry by ServiceNow into cybersecurity”
5
Armis sale to ServiceNow could yield $4 billion windfall for Insight Partners
More news
Helsinn
1 stories about Helsinn
Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court
05.12.18
|
Lilach Baumer
Teva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
